Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Adv Drug Deliv Rev. 2016 Apr 29;101:143–166. doi: 10.1016/j.addr.2016.04.022

Fig. 20.

Fig. 20

Cocrystal solubility advantage as a function of drug solubilization for CBZ-SAC, PTB-CAF and DNZ-HBA cocrystals, decreases with increasing SR in a predictable way that identifies the SR limit above which cocrystal SA is overturned, the transition point. Full lines represent cocrystal SA predicted from equation (9) using only the experimentally determined cocrystal SAaq. The dotted line indicates the line of equal cocrystal and drug solubilities. Solubilizing agents correspond to those in Figs. 12 and 13.